Mursla, a UK-based oncology-focused spinout of Tokyo Institute of Technology (TIT), has partnered University of Cambridge to build a prototype of its diagnostic technology, Business Weekly reported on Tuesday.
The spinout will be based at University of Cambridge’s IdeaSpace innovation hub, which generally offers its services to any early-stage spinout or startup based in Cambridge. IdeaSpace offers access to the university’s links with other faculties, governments and agencies.
Mursla has developed diagnostic liquid biopsy nanostructures to better analyse the health status of a cancer patient. The company claims the nanostructures can draw more predictive power than alternatives such as deep gene sequencing.
TIT recently launched a venture capital fund aimed at assisting spinouts and student startups from the university, according to its new year message for 2017, though no further details were disclosed.
Pierre Arsène, co-founder and CEO of Mursla, said: “Our breakthrough technology enables the mass fabrication of novel devices designed to find the next generation of those materials.
“Instead of incorporating nanostructures to test their semiconducting properties, we decided to integrate the smallest biomolecules such as proteins so that we can analyse, detect and differentiate them for medical diagnostics purposes via their unique resistance [and] capacitance.”
